Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$38.90M$38.90M+12.2% vs Q1 2024 Net Income$2.64M$2.64MN/M vs Q1 2024 EPS Diluted$0.01$0.01N/M vs Q1 2024 Gross Profit$30,446,000+16.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$8,870,000N/M Free Cash Flowderived-$8,979,000— Margins · derivedGross margin78.3%+2.6 pt vs Q1 2024
Operating margin8.1%+21.9 pt vs Q1 2024
Net margin6.8%+15.9 pt vs Q1 2024
ended Mar 31, 2025 · filed May 6, 2025 · 36 d after period end